checkAd
    Startseite > Aktien > Aclaris Therapeutics > Nachrichten
    Aclaris Therapeutics Aktie
    1,0100
     
    USD
    -1,94 %
    -0,0200 USD
    Letzter Kurs 08.06.24 Nasdaq
    1,0100
     
    USD
    7.200 STK
    Geldkurs 07.06.24
    1,0200
     
    USD
    3.100 STK
    Briefkurs 07.06.24
    ISIN: US00461U1051 · WKN: A1412H · SYM: ACRS · USA

    Neueste Nachrichten

    Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    06.06.24 · globenewswire · Aclaris Therapeutics
    Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
    07.05.24 · globenewswire · Aclaris Therapeutics
    Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
    30.04.24 · globenewswire · Aclaris Therapeutics
    Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
    27.02.24 · globenewswire · Aclaris Therapeutics
    Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
    16.01.24 · globenewswire · Aclaris Therapeutics
    Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
    10.01.24 · globenewswire · Aclaris Therapeutics
    Aclaris Therapeutics Provides Corporate Update
    19.12.23 · globenewswire · Aclaris Therapeutics
    Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
    13.11.23 · globenewswire · Aclaris Therapeutics
    Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
    06.11.23 · globenewswire · Aclaris Therapeutics
    Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
    03.10.23 · globenewswire · Aclaris Therapeutics
    Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
    20.09.23 · globenewswire · Aclaris Therapeutics
    Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor
    18.09.23 · globenewswire · Aclaris Therapeutics